Research programme: TIE 2 receptor kinase inhibitors - Pfizer
Alternative Names: CE-355774; PF-371989Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action TIE-2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 13 Aug 2009 This programme is still in active development
- 29 Sep 2006 Preclinical trials in Cancer in USA (unspecified route)